An Exploratory Study of MT-1303 in Subjects With Systemic Lupus Erythematosus (a Multicenter, Open-label Study)
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Amiselimod (Primary) ; Corticosteroid; Immunosuppressants
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 13 Jun 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 27 Jan 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.